Abstract

PurposeIMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported outcome measures collected at serial time points are now reported.Patients and MethodsIMPORT LOW recruited women with low-risk breast cancer after breast-conserving surgery. Patients were randomly assigned to 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and Breast Cancer–Specific Module, Body Image Scale, protocol-specific items, and the Hospital Anxiety and Depression Scale were administered at baseline, 6 months, and 1, 2, and 5 years. Patterns of moderate/marked adverse effects (AEs) were assessed using longitudinal regression models, and baseline predictors were investigated.ResultsA total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years. Breast appearance change was most prevalent and persisted over time (approximately 20% at each time point). Prevalence of breast hardness, pain, oversensitivity, edema, and skin changes reduced over time (P < .001 for each), whereas breast shrinkage increased (P < .001). Analysis by treatment group showed average number of AEs per person was lower in partial-breast (incidence rate ratio, 0.77; 95% CI, 0.71 to 0.84; P < .001) and reduced-dose (incidence rate ratio, 0.83; 95% CI, 0.76 to 0.90; P < .001) versus whole-breast group and decreased over time in all groups. Younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression were baseline predictors of subsequent AE reporting.ConclusionMost AEs reduced over time, with fewer AEs in the partial-breast and reduced-dose groups. Baseline predictors for AE reporting were identified. These findings will facilitate informed discussion and shared decision making for future patients receiving moderately hypofractionated breast radiotherapy.

Highlights

  • Trials of hypofractionated whole-breast radiotherapy after breast-conserving surgery have demonstrated that 40 Gy in 15 fractions is safe and effective, with patients reporting lower levels of moderate/marked adverse effects (AEs) compared with 50 Gy in 2-Gy daily fractions.[1,2] the 3-week regimen tested in the START-B (UK Standardisation of Breast Radiotherapy B) trial[1] has become standard of care in the UnitedKingdom for whole-breast radiotherapy and is used internationally.[3]

  • A total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years

  • Analysis by treatment group showed average number of AEs per person was lower in partial-breast and reduced-dose versus whole-breast group and decreased over time in all groups

Read more

Summary

Introduction

Trials of hypofractionated whole-breast radiotherapy after breast-conserving surgery have demonstrated that 40 Gy in 15 fractions is safe and effective, with patients reporting lower levels of moderate/marked adverse effects (AEs) compared with 50 Gy in 2-Gy daily fractions.[1,2] the 3-week regimen tested in the START-B (UK Standardisation of Breast Radiotherapy B) trial[1] has become standard of care in the UnitedKingdom for whole-breast radiotherapy and is used internationally.[3]. LOW (Intensity-Modulated and Partial-Organ Radiotherapy Low Risk) investigated efficacy of partial-breast versus whole-breast irradiation using standard UK hypofractionated radiotherapy.[4] The randomized trial schedules were: 40 Gy whole-breast radiotherapy (control); 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose group); and 40 Gy partial-breast radiotherapy only (partial-breast group) in 15 daily fractions, using simple intensity-modulated radiotherapy (IMRT; Fig 1). IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy compared with standard wholebreast radiotherapy for local relapse, with similar or fewer late normal-tissue AEs at 5 years using clinician assessments, patientreported outcome measures (PROM), and serial photographs.[4] These published results demonstrated that at 5 years, patients generally reported fewer moderate/marked AEs for skin changes, breast appearance change, smaller breast, and harder/firmer breast to touch in the partial-breast group compared with the wholebreast group, the reduction was only statistically significant (P , .001) for change in breast appearance.[4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call